Loading...
OTCM
QNTPF
Market cap2.53bUSD
Oct 21, Last price  
0.74USD
1D
0.00%
IPO
-25.88%
Name

QuantumPharm Inc

Chart & performance

D1W1MN
OTCM:QNTPF chart
P/E
139.98
P/S
21.58
EPS
0.04
Vol. 1Y
—
Shs. 5Y
11.39%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
782m
+193.45%
746,566,000983,738,0001,373,606,0001,559,223,0001,494,105,0001,322,598,0001,241,824,000646,548,0000000174,420,000266,433,000781,850,226
Net income
121m
P
148,591,000221,826,000250,770,000245,621,000242,570,000266,406,000181,259,000-1,769,781,000-26,588,000-14,665,000-36,033,000-28,284,000-1,914,384,000-1,516,606,000120,544,289
CFO
-140m
L-70.83%
69,102,000181,568,000173,621,000242,043,000381,459,000368,478,000335,657,000-1,090,0005,717,000655,000-567,564,000-478,681,000-139,618,511

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

XtalPi Holdings Limited functions as an investment holding company, delivering sophisticated drug discovery and intelligent automation solutions across key markets including China, the United States, Europe, South Korea, and Japan. Its comprehensive drug discovery services encompass the entire research and development process, ranging from target validation and hit identification to lead generation, lead optimization, and PCC nomination. These services are adept across diverse therapeutic modalities, such as small molecules, antibodies, peptides, ADCs, and PROTACs. The company's intelligent automation solutions specifically utilize artificial intelligence and automation to facilitate the accelerated discovery and research of novel drugs and materials. Established in 2015 and based in Shenzhen, China, the firm was formerly known as QuantumPharm Inc. before officially changing its name to XtalPi Holdings Limited in December 2024.
IPO date
Jun 13, 2024
Employees
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT